{"id":"W4385230266","doi":"10.1093/bjd/ljad252","title":"Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)","year":2023,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Dermatrials Research; Probity Medical Research; University of British Columbia","funders":"National Institutes of Health; AbbVie; Boehringer Ingelheim","keywords":"Apremilast; Medicine; Psoriasis Area and Severity Index; Psoriasis; Randomized controlled trial; Internal medicine; Secukinumab; Clinical endpoint; Dermatology; Psoriatic arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004189373,0.001267363,0.00266972,0.0003740389,0.0003568116,0.001165307,0.0008833556,0.001794989,0.00485577],"category_scores_gemma":[0.003149751,0.0007707569,0.002563862,0.0003380031,0.0009581347,0.001209402,0.0004571422,0.002643695,0.0007891273],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007005669,"about_ca_system_score_gemma":0.001276561,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003979823,"about_ca_topic_score_gemma":0.0009856246,"domain_scores_codex":[0.9980597,0.001149982,0.0001799781,0.0002885641,0.0001768343,0.0001449608],"domain_scores_gemma":[0.9974006,0.0007542075,0.0007597754,0.0002190153,0.0001870618,0.0006793949],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.973134,0.009292628,0.0007478206,0.0003203629,0.000944807,0.00001815757,0.00005143964,0.0001287183,0.003385135,0.00004484455,0.0003122462,0.01161981],"study_design_scores_gemma":[0.8470243,0.1488571,0.002629814,0.00002026351,0.0005082826,0.0000279087,0.0000148179,0.0001991691,0.0003606405,0.00005647765,0.0002907109,0.00001037832],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9909458,0.003167558,0.0006534979,0.0003517679,0.000260559,0.002560139,0.0008384664,0.00008056147,0.001141642],"genre_scores_gemma":[0.990034,0.001809069,0.002109187,0.0008204398,0.0004718249,0.002502052,0.001026124,0.0000224965,0.001204675],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00485577,"threshold_uncertainty_score":0.02215576,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06904877460295726,"score_gpt":0.3528525986404932,"score_spread":0.283803824037536,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}